Marc Stapley, the Chief Executive Officer of Veracyte, has executed a sale of company shares valued at $6.9 million. This transaction reflects Stapley's ongoing management of his investment portfolio. The sale was disclosed in a regulatory filing, which is a standard requirement for executives in publicly traded companies. Veracyte, a genomic diagnostics company, continues to focus on advancing its innovative technologies in the healthcare sector.
Don't miss out on breaking stories and in-depth articles.
